K
Kenneth C. Kalunian
Researcher at University of California, San Diego
Publications - 228
Citations - 21989
Kenneth C. Kalunian is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Lupus erythematosus & Systemic lupus erythematosus. The author has an hindex of 63, co-authored 199 publications receiving 18490 citations. Previous affiliations of Kenneth C. Kalunian include University of Utah & University of Southern California.
Papers
More filters
Journal ArticleDOI
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Michelle Petri,Ana Maria Orbai,Graciela S. Alarcón,Caroline Gordon,Joan T. Merrill,Paul R. Fortin,Ian N. Bruce,David A. Isenberg,Daniel J. Wallace,Ola Nived,Gunnar Sturfelt,Rosalind Ramsey-Goldman,Sang Cheol Bae,John G. Hanly,Jorge Sanchez-Guerrero,Ann E. Clarke,Cynthia Aranow,Susan Manzi,Murray B. Urowitz,Dafna D. Gladman,Kenneth C. Kalunian,Melissa Costner,Victoria P. Werth,Asad Zoma,Sasha Bernatsky,Guillermo Ruiz-Irastorza,Munther A. Khamashta,Søren Jacobsen,Jill P. Buyon,Peter J. Maddison,Mary Anne Dooley,Ronald F van Vollenhoven,Ellen M. Ginzler,Thomas Stoll,Christine A. Peschken,Joseph L. Jorizzo,Jeffrey P. Callen,S. Sam Lim,Barri J. Fessler,Murat Inanc,Diane L. Kamen,Anisur Rahman,Kristjan Steinsson,Andrew G. Franks,Lisa Sigler,Suhail Hameed,Hong Fang,Ngoc Minh Pham,Robin L. Brey,Michael H. Weisman,Gerald McGwin,Laurence S. Magder +51 more
TL;DR: The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria in order to improve clinical relevance, meet stringent methodology requirements, and incorporate new knowledge regarding the immunology of SLE.
Journal ArticleDOI
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.
Dafna D. Gladman,Ellen M. Ginzler,Charles H. Goldsmith,Paul R. Fortin,Matthew H. Liang,MB Urowitz,Paul A. Bacon,Stefano Bombardieri,John G. Hanly,Elaine M Hay,David A. Isenberg,Jones Jv,Kenneth C. Kalunian,Peter J. Maddison,Ola Nived,Michelle Petri,Martin Richter,Jorge Sanchez-Guerrero,M L Snaith,Gunnar Sturfelt,Deborah P M Symmons,Asad Zoma +21 more
TL;DR: This damage index for SLE records damage occurring in patients with SLE regardless of its cause and was demonstrated to have content, face, criterion, and discriminant validity.
Journal ArticleDOI
Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus
Michelle Petri,Mimi Y. Kim,Kenneth C. Kalunian,Jennifer M. Grossman,Bevra H. Hahn,Lisa R. Sammaritano,Michael D. Lockshin,Joan T. Merrill,H. Michael Belmont,Anca Askanase,W. Joseph McCune,Michelene Hearth-Holmes,Mary Anne Dooley,Joan M. Von Feldt,Alan Friedman,Mark Tan,John A. Davis,Cronin Me,Betty Diamond,Meggan Mackay,Lisa Sigler,Michael Fillius,Ann Rupel,Frederick Licciardi,Jill P. Buyon +24 more
TL;DR: It is indicated that oral contraceptives do not increase the risk of flare among women with systemic lupus erythematosus whose disease is stable.
Journal ArticleDOI
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus.
Dafna D. Gladman,Murray B. Urowitz,Charles H. Goldsmith,Paul R. Fortin,Ellen M. Ginzler,Caroline Gordon,John G. Hanly,David A. Isenberg,Kenneth C. Kalunian,Ola Nived,Michelle Petri,Jorge Sánchez-Guerrero,M L Snaith,Gunnar Sturfelt +13 more
TL;DR: Physicians from different centers are able to assess patients with SLE in a reproducible way, using the SLEDAI to assess disease activity and the SLICC/ACR Damage Index to assess accumulated damage.
Journal ArticleDOI
Anifrolumab, an Anti–Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
Richard Furie,Munther A. Khamashta,Joan T. Merrill,Victoria P. Werth,Kenneth C. Kalunian,Philip Brohawn,G. Illei,Jorn Drappa,L. Wang,Stephen Yoo +9 more
TL;DR: To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with moderate‐to‐severe systemic lupus erythematosus (SLE).